Rational redesign of antigen binding domain improves in vivo efficacy of the CD22-CAR.

ABSTRACT: Chimeric antigen receptor (CAR) T cells targeting CD19 are highly effective against B lineage malignancies. However, about half of patients either fail to achieve complete remission (in the case of lymphoma) or they relapse (in the case of acute lymphoblastic leukemia). CD22 represents an alternative highly B lineage-restricted target. Although CD22-targeted CAR-T cells are clinically active, targeting this antigen has proven difficult relative to CD19, attributable, in part, to lower expression levels. Commonly, patients relapse or progress with reduced CD22 expression compared to pre-treatment, contrasting with the loss of CD19 expression typically observed after CD19-CAR therapy. Prior work demonstrated that an antigen-independent "tonic" signaling CD22-CAR has enhanced clinical efficac

SUBMITTER: DeGolier KR 

PROVIDER: S-EPMC12866949 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature